50th International Liver Congress: update on viral hepatitis 22–26 April 2015, Vienna, Austria
AbstractThe European Association for the Study of the Liver’s 50th International Liver Congress presented a range of exciting new data in viral hepatitis. Several successful applications of novel direct-acting antivirals (DAA; Table 1) in previously ‘hard-to-treat’ patient populations were reported and the arrival of further DAAs was heralded with impressive efficacy data. With success in the HCV domain now well established, greater attention is being focused on methods of clearing HBV infection. Results of novel combinations of existing therapies in the clinical domain were presented, while a proliferation of experimental approaches for targeting infected hepatocytes in vitro and in vivo show great promise.
Hepatitis C (HCV)
|1435699181JVE 1-3 easl.pdf|